Necrotizing Autoimmune Myopathy: A Case Report on Statin-Induced Rhabdomyolysis.
anti-hmg coa antibody
atorvastatin
creatinine kinase
general internal medicine
medicine
myopathy
necrotizing autoimmune
rhabdomyolysis
rheumatology
statin
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
19
11
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Statin-induced necrotizing myopathy (SINM) is an uncommon but severe complication associated with statin medication. SINM can develop at any point after a person starts taking steroids. It is now being acknowledged as a component of the broader category of "statin-induced myopathy." Like other immune-mediated necrotizing muscle diseases, statin-induced myositis is identified by weakness in proximal muscles, increased serum creatine kinase (CK) levels, and, in some cases, dysphagia and respiratory distress. In addition, there is evidence of muscle cell damage when examined under a microscope, occurring with minimal or no infiltration of inflammatory cells. Diagnosing SINM promptly is frequently challenging due to its unpredictable development over time, with symptoms sometimes emerging many years after the initial exposure to statins. One distinctive characteristic of SINM is the continued presence of muscle inflammation and elevated CK levels even after discontinuing statin treatment. Currently, no clinical trials are available to guide how to manage statin-induced immune-mediated necrotizing myopathy (IMNM). Here, we present a case of a 42-year-old woman diagnosed with SINM and was found to have persistently elevated CPK despite discontinuation of statins. Our case also suggests that intravenous (IV) immunoglobins and steroids are an effective and well-tolerated alternative to immunosuppressants.
Identifiants
pubmed: 38024077
doi: 10.7759/cureus.49065
pmc: PMC10660882
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e49065Informations de copyright
Copyright © 2023, Altaf et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2015 Oct 22;373(17):1680-2
pubmed: 26488714
Rheumatology (Oxford). 2017 May 1;56(5):787-794
pubmed: 28096458
Adv Pharm Bull. 2014;4(3):249-54
pubmed: 24754008
Neuromuscul Disord. 2018 Jan;28(1):87-99
pubmed: 29221629
Nat Rev Rheumatol. 2018 May;14(5):279-289
pubmed: 29593343
Semin Arthritis Rheum. 2019 Dec;49(3):420-429
pubmed: 31109639
Arthritis Rheum. 2010 Sep;62(9):2757-66
pubmed: 20496415
J Clin Med. 2020 Jul 08;9(7):
pubmed: 32650400
Expert Rev Clin Immunol. 2018 Mar;14(3):215-224
pubmed: 29473763
J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S58-71
pubmed: 24793443
N Engl J Med. 2016 Feb 18;374(7):664-9
pubmed: 26886523
Cell Mol Life Sci. 2006 Oct;63(19-20):2415-25
pubmed: 17013560
Arthritis Care Res (Hoboken). 2012 Feb;64(2):269-72
pubmed: 21972203
Rheumatology (Oxford). 2015 Nov;54(11):2010-4
pubmed: 26109604
Br J Clin Pharmacol. 2015 Sep;80(3):363-71
pubmed: 26032930
Brain. 2016 Aug;139(Pt 8):2131-5
pubmed: 27086869
PLoS One. 2015 Oct 28;10(10):e0141616
pubmed: 26509687
JACC Case Rep. 2020 Feb 26;2(3):440-443
pubmed: 34317259
Korean Circ J. 2016 May;46(3):275-306
pubmed: 27275165
Muscle Nerve. 2010 Feb;41(2):185-90
pubmed: 19813188
Reumatologia. 2023;61(4):271-282
pubmed: 37745145
Arh Hig Rada Toksikol. 2017 Dec 20;68(4):254-260
pubmed: 29337684
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 16;6(1):e513
pubmed: 30345336
SAGE Open Med Case Rep. 2023 Jan 17;11:2050313X221150583
pubmed: 36686203
Cureus. 2020 May 5;12(5):e7963
pubmed: 32523820
Arthritis Res Ther. 2020 Jan 8;22(1):5
pubmed: 31915059
Front Cardiovasc Med. 2021 May 20;8:687585
pubmed: 34095267
Curr Rheumatol Rep. 2015 Dec;17(12):72
pubmed: 26515574
Adv Clin Chem. 2016;73:127-68
pubmed: 26975972